PHASE I or MULTIPLE SITES:

• Phase I study of TOMUDEX and GEMCITABINE in treatment of advanced cancer
  
• Phase I and pharmacokinetics study of SarCNU in patients with advanced cancer
  
• A Prospective, Multicentre, Open-Label Study for the Long-Term Evaluation of the Safety, Tolerability and Efficacy of NEOVASTAT (Æ 941) Administered Orally in Patients with Solid Tumors that are Refractory to Standard therapies or for Whom no Standard Therapies are Available.
  

OVARIAN CANCER:

• A multicenter phase iib clinical trial of OVAREX™ MAb B43.13 for the neo-adjuvant treatment of advanced ovarian cancer
  
• A phase II trial if IV-L-PAM and BSO in patients with relapsed or refractory ovarian cancer
  
• A phase II study of VX-710 + PACLITAXEL in women with advanced ovarian cancer that is refractory to PACLITAXEL therapy with or without cisplatin
  
• Study C/198-103: Phase II Trial of Chemotherapy Alone vs. Chemotherapy Plus SCH 58500 in Stage III Persistent, Ovarian and Primary Peritoneal Cancer Patients.
  

BREAST CANCER:

• A phase II trial of 5-AZA-2'- DEOXYCYTIDINE in patients with advanced metastatic breast cancer with tumor accessible for biopsy
  
• Multicenter phase II study of VX-710 in combination with PACLITAXEL in women with advanced carcinoma of the breast that is refractory to PACLITAXEL
  
• A study to compare the bioequivalence of two formulations of 20 MG NOLVADEX tablets taken once daily
  
• A Prospective, Multicentre, Open-Label Study for the Long-Term Evaluation of the Safety, Tolerability and Efficacy of NEOVASTAT (Æ 941) Administered Orally in Patients with Solid Tumors that are Refractory to Standard therapies or for Whom no Standard Therapies are Available.
  
• Phase II Multicenter, Double-Blind, Randomized, Placebo-Controlled, Multi-Regimen Study of CJ-11,974 for the Control of High Dose Cisplatin Chemotherapy-Induced Emesis
  

HEAD & NECK CANCER:

• A phase I - II study of LEUKOCYTE INTERLEUKIN, injection, CYCLOPHOSPHAMIDE, injection, INDOMETHACIN, and oral ZINC in patients with locally recurrent or locally metastatic head and neck cancer
  
• A phase II trial of electroporation therapy (EPT) using the GENETRONICS, INC. MEDPULSER TM system and INTRATUMOR BLEOMYCIN in patients with squamous cell carcinoma of the head and neck who have failed standard therapy
  

COLORECTAL CANCER:

• A Prospective, Multicentre, Open-Label Study for the Long-Term Evaluation of the Safety, Tolerability and Efficacy of Neovastat (Æ 941) Administered Orally in Patients with Solid Tumors that are Refractory to Standard therapies or for Whom no Standard Therapies are Available.
  

CUTANEOUS T-CELL LYMPHOMA:

• Phase 2-3 evaluation of TARGRETIN(TM) in patients with refractory or persistent early stage cutaneous t-cell lymphoma
  

METASTATIC MELANOMA:

• Multi-Center, Randomized Open-Label Study To Evaluate The Safety And Efficacy Of Combined Immunotherapy With Subcutaneous INTERLEUKIN-2, INTERFERON-µ2B, And MAXAMINE™ Versus Intravenous DACARBAZINE(DTIC) Alone In Patients With Advanced Malignant Melanoma
  

STUDIES UNDER REVIEW - ACTIVATION PENDING:

• A phase II study of SCH58500 in combination with chemotherapy and chemotherapy alone in patinets with colorectal cancer metastatic to the liver.
  
• A multi-institutional phase II study of CYCLOPHOSPHAMIDE, PACLITAXEL CISPLATIN with G-CSF for patients with newly diagnosed advanced stage ovarian cancer.
  
• A phase I/II study to assess the safety and efficacy of low doses of BETATHINE in patients with advanced myeloma.
  
• A phase II study of EPIRUBICIN plus TOMUDEX in patients with advanced cancer.
  
• A phase II study of ELL-12, a LIPOSOME encapsulated ether lipid in refractory cancers.
  
• A phase I study of oral ZD1839 given daily in patients with solid epithelial tumors.
  
• A phase II study of the efficacy and safety of oral GD0039 in patients with locally advanced or metastatic renal cell carcinoma and in 5-fluorouracil-resistant patients with locally advanced or metastatic colorectal cancer.